DR. EMMANUELLE DEPONGE
Dr. Emmanuelle Deponge serves as Partner and Investment Director at Apicap. Emmanuelle has had a number of successful company exits in her role at Apicap including the sale of Trophos (developing treatment for spinal muscular atrophy, AS) to Roche in 2015 for €470M.
Prior to joining OTC, Emmanuelle was in charge of the Technology Transfer Office at the Institut Curie. She has more than 15 years of experience in the Life science sector, in particular within the framework of in & out licensing technology transfer and the management of patent portfolios.
She has held various positions in academic and industrial organizations in particular as Alliance Manager of a biotech company in the field of gene therapy and as Technology Transfer Director of health products with the Curie Institute and with the company Généthon.
In 2007, she joined OTC Asset Management, an independent venture fund company, in charge of the life science sector. OTC was later acquired by Apicap.
Emmanuelle holds a PhD in Life Sciences and she also studied intellectual property law.